$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000147793224000713 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$245.8K	$184.5K	$342.5K
YoY Change	2.07%	-46.11%	-70.65%
% of Gross Profit
Research & Development	$67.52K	$52.75K	$0.00
YoY Change			-100.0%
% of Gross Profit
Depreciation & Amortization	$370.00	$760.00	$370.00
YoY Change	-2.63%	105.41%	362.5%
% of Gross Profit
Operating Expenses	$353.0K	$339.9K	$539.0K
YoY Change	-8.85%	-36.93%	-87.35%
Operating Profit	-$353.0K	-$339.9K	-$539.0K
YoY Change	-8.85%	-36.93%	-87.35%
Interest Expense	$28.56K	$846.7K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$31.13K	-$867.0K	-$755.3K
YoY Change	1146.28%	14.78%	-40.36%
Pretax Income	-$384.1K	-$1.207M	-$1.294M
YoY Change	-1.45%	-6.76%	-76.58%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$384.1K	-$1.207M	-$1.294M
YoY Change	4.05%	-6.76%	-76.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	445.0M shares	401.0M shares	366.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$373.6K	$38.98K	$227.5K
YoY Change	258.93%	-82.87%	-89.22%
Cash & Equivalents	$373.6K	$38.98K	$119.6K
Short-Term Investments			$107.9K
Other Short-Term Assets	$7.680K	$6.280K	$23.07K
YoY Change	-47.93%	-72.78%	50.1%
Inventory
Prepaid Expenses	$7.684K	$6.284K	$10.52K
Receivables	$8.160K	$8.160K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$389.4K	$53.43K	$250.6K
YoY Change	227.72%	-78.68%	-88.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.373K	$4.751K	$6.263K
YoY Change	-25.69%	-24.14%	27.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.55K	$12.55K
YoY Change
Total Long-Term Assets	$62.37K	$75.58K	$112.5K
YoY Change	-75.49%	-32.82%	-27.05%
TOTAL ASSETS
Total Short-Term Assets	$389.4K	$53.43K	$250.6K
Total Long-Term Assets	$62.37K	$75.58K	$112.5K
Total Assets	$451.8K	$129.0K	$363.1K
YoY Change	21.04%	-64.47%	-84.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.058M	$1.089M	$158.0K
YoY Change	458.7%	589.42%	565.37%
Accrued Expenses	$58.38K	$67.31K	$114.7K
YoY Change	-32.25%	-41.29%	282.17%
Deferred Revenue
YoY Change
Short-Term Debt	$7.426M	$5.850M	$5.850M
YoY Change	23.03%	0.0%	711.31%
Long-Term Debt Due		$860.0K
YoY Change
Total Short-Term Liabilities	$8.617M	$7.942M	$6.198M
YoY Change	34.93%	28.13%	655.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$30.00K	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$5.390K	$66.94K
YoY Change	-100.0%	-91.95%	-43.07%
Total Long-Term Liabilities	$0.00	$35.39K	$66.94K
YoY Change	-100.0%	-47.13%	-43.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.617M	$7.942M	$6.198M
Total Long-Term Liabilities	$0.00	$35.39K	$66.94K
Total Liabilities	$8.617M	$7.977M	$6.265M
YoY Change	33.86%	27.33%	567.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.55M	-$25.17M	-$22.67M
YoY Change	10.93%	11.04%	126.01%
Common Stock	$4.550K	$4.450K	$3.769K
YoY Change	19.14%	18.07%	5.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$8.165M	-$7.848M	-$3.089M
YoY Change
Total Liabilities & Shareholders Equity	$451.8K	$129.0K	$363.1K
YoY Change	21.04%	-64.47%	-84.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$384.1K	-$1.207M	-$1.294M
YoY Change	4.05%	-6.76%	-76.58%
Depreciation, Depletion And Amortization	$370.00	$760.00	$370.00
YoY Change	-2.63%	105.41%	362.5%
Cash From Operating Activities	-$415.4K	-$334.5K	-$378.5K
YoY Change	345.48%	-11.62%	-88.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$131.8K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$131.8K	$0.00
YoY Change	-100.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	750.0K	220.0K	0.000
YoY Change	177.78%		-100.0%
NET CHANGE
Cash From Operating Activities	-415.4K	-334.5K	-378.5K
Cash From Investing Activities	0.000	131.8K	0.000
Cash From Financing Activities	750.0K	220.0K	0.000
Net Change In Cash	334.6K	17.36K	-378.5K
YoY Change	-2257.25%	-104.59%	-120.7%
FREE CASH FLOW
Cash From Operating Activities	-$415.4K	-$334.5K	-$378.5K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$415.4K	-$334.5K	-$378.5K
YoY Change	345.48%	-11.62%	-88.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001481504
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	445044644	shares
CY2023	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21250000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54277
	dei	Entity Registrant Name EntityRegistrantName	XERIANT, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1519178
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Innovation Centre 1
	dei	Entity Address Address Line2 EntityAddressAddressLine2	3998 FAU Boulevard, Suite 309
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
	dei	City Area Code CityAreaCode	561
	dei	Local Phone Number LocalPhoneNumber	491-9595
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	445044644	shares
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	30000	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2023Q4	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	102650	usd
CY2022Q4	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	270888	usd
	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	154345	usd
	xeri	Consulting And Advisory Fees ConsultingAndAdvisoryFees	726461	usd
CY2023Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	77000	usd
CY2022Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	118000	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	174500	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	212000	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71513	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69620	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	121390	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	159616	usd
CY2023Q4	us-gaap	Professional Fees ProfessionalFees	34691	usd
CY2022Q4	us-gaap	Professional Fees ProfessionalFees	78568	usd
	us-gaap	Professional Fees ProfessionalFees	125005	usd
	us-gaap	Professional Fees ProfessionalFees	168628	usd
CY2023Q4	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1336	usd
CY2022Q4	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1943	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3858	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	8299	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52753	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79735	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	339943	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	539019	usd
	us-gaap	Operating Expenses OperatingExpenses	658833	usd
	us-gaap	Operating Expenses OperatingExpenses	1275004	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-339943	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-539019	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-658833	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1275004	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	461842	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48000	usd
CY2022Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2022Q3	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	1918393	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	306170	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4817521	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-5506663	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	846654	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	867328	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q4	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	0	usd
CY2022Q4	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	0	usd
	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	-2448	usd
	xeri	Decrease Increase In Fair Value Of Convertible Bridge Loans DecreaseIncreaseInFairValueOfConvertibleBridgeLoans	0	usd
CY2023Q4	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	0	usd
CY2022Q4	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	-65722	usd
	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	0	usd
	xeri	Gain Loss From Ebenberg Jv GainLossFromEbenbergJv	-115050	usd
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20298	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-689621	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20298	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4259987	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-866952	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-755343	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-890074	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4836879	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1206895	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1294362	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1548907	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6111883	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1206895	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1294362	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1548907	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6111883	usd
CY2023Q4	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-7712	usd
CY2022Q4	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-7307	usd
	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-15634	usd
	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-14732	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1199183	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1287055	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1533273	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6097151	usd
CY2023Q4	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
CY2022Q4	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.00
	xeri	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.02
CY2023Q4	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	423465699	shares
CY2022Q4	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	373345770	shares
	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	408569551	shares
	xeri	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	369415435	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-6620100	usd
CY2023Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	66000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-342012	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6896112	usd
CY2023Q4	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	-1	usd
CY2023Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	255115	usd
CY2022Q4	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	usd
CY2022Q4	xeri	Fair Value Of Warrants Associated With Convertible Debt FairValueOfWarrantsAssociatedWithConvertibleDebt	689621	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1206895	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7847893	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2961705	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	209747	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-1294362	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5901657	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	461842	usd
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	0	usd
	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	2608014	usd
	us-gaap	Development Costs DevelopmentCosts	5500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25171734	usd
CY2023Q4	xeri	Working Capital Deficit WorkingCapitalDeficit	-7888081	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	515917	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	209747	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79735	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52753	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
	us-gaap	Advertising Expense AdvertisingExpense	3858	usd
	us-gaap	Advertising Expense AdvertisingExpense	8299	usd
CY2023Q4	us-gaap	Advertising Expense AdvertisingExpense	1336	usd
CY2022Q4	us-gaap	Advertising Expense AdvertisingExpense	1943	usd
	xeri	Warrants Issued WarrantsIssued	104802161	shares
	xeri	Warrants Issued WarrantsIssued	105512161	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21250000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21250000	shares
	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	723513736	shares
	xeri	Stock Issued During Period Convertible Notes Payable StockIssuedDuringPeriodConvertibleNotesPayable	49166667	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	733895000	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	769895000	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1583460897	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	945823828	shares
	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	26550	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	26958	usd
CY2023Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	13266	usd
CY2022Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	13332	usd
CY2023Q4	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	220448	usd
CY2023Q4	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-162165	usd
CY2023Q2	xeri	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	-137537	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58283	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	82911	usd
CY2023Q4	xeri	Office Leas Operating Lease Liability OfficeLeasOperatingLeaseLiability	65202	usd
CY2023Q2	xeri	Office Leas Operating Lease Liability OfficeLeasOperatingLeaseLiability	92196	usd
CY2023Q4	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-59810	usd
CY2023Q2	xeri	Operating Lease Liability Current Portion OperatingLeaseLiabilityCurrentPortion	-55999	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5392	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36197	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	31405	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	37112	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	68517	usd
CY2023Q4	xeri	Present Value Discount PresentValueDiscount	-3315	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	65202	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5850000	usd
CY2023Q4	xeri	Convertible Notes Payable Aggregate Face Value ConvertibleNotesPayableAggregateFaceValue	270000	usd
CY2023Q4	xeri	Exercise Price ExercisePrice	0.09
CY2023Q4	xeri	Conversion Price Per Share ConversionPricePerShare	0.01
CY2023Q4	xeri	Loans Fair Value LoansFairValue	249702	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	247254	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	0	usd
CY2023	xeri	Proceeds From Convertible Bridge Loans ProceedsFromConvertibleBridgeLoans	189886	usd
	us-gaap	Deposit Assets Effect Of Change In Present Value Assumptions Recorded As Expense DepositAssetsEffectOfChangeInPresentValueAssumptionsRecordedAsExpense	2448	usd
CY2023	us-gaap	Deposit Assets Effect Of Change In Present Value Assumptions Recorded As Expense DepositAssetsEffectOfChangeInPresentValueAssumptionsRecordedAsExpense	57368	usd
	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	-249702	usd
CY2023	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	0	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	0	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	247254	usd
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	389433144	shares
	xeri	Converted Interest Into Shares Of Common Stock ConvertedInterestIntoSharesOfCommonStock	20011500	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20968750	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd

Files In Submission

Name	View Source	Status
0001477932-24-000713-index-headers.html	Edgar Link	pending
0001477932-24-000713-index.html	Edgar Link	pending
0001477932-24-000713.txt	Edgar Link	pending
0001477932-24-000713-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20231231.xsd	Edgar Link	pending
xeri_10q.htm	Edgar Link	pending
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending
xeri-20231231_def.xml	Edgar Link	unprocessable
xeri-20231231_lab.xml	Edgar Link	unprocessable
xeri-20231231_pre.xml	Edgar Link	unprocessable
xeri_10q_htm.xml	Edgar Link	completed
xeri-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2024 Q1 Form 10-Q Financial Statement

#000147793224000713 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2024 Q1 Form 10-Q Financial Statement

#000147793224000713 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri